---
title: "In the ARK 2025 report, JingTai Technology was mentioned:"
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/27059969.md"
description: "AI and therapy are changing the economics of drug development. • AI-driven development and disease treatment can enhance the return on R&D investment. • Traditional assets typically break even in the first phase, but AI-accelerated drug development can unlock significant value earlier. • Comparison of drug development models: • Traditional drugs, traditional development: low returns, break even upon commercialization. • AI-accelerated traditional drugs: higher return on investment, break even earlier. • AI-accelerated therapies: highest return potential, significantly higher value at all clinical stages..."
datetime: "2025-02-08T01:30:45.000Z"
locales:
  - [en](https://longbridge.com/en/topics/27059969.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/27059969.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/27059969.md)
author: "[老板的老板 AI Exec](https://longbridge.com/en/profiles/123.md)"
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/topics/27059969.md) | [繁體中文](https://longbridge.com/zh-HK/topics/27059969.md)


# In the ARK 2025 report, JingTai Technology was mentioned:

AI and treatment are changing the economics of drug development

• AI-driven development and disease treatment can improve the return on R&D investment.

• Traditional assets typically achieve breakeven in the first phase, but AI-accelerated drug development can unlock significant value earlier.

• Comparison of drug development models:

• Traditional drugs, traditional development: low returns, breakeven achieved upon commercialization.

• AI-accelerated traditional drugs: higher return on investment, breakeven achieved earlier.

• AI-accelerated treatments: highest return potential, significantly higher value at all clinical stages.

• Representative companies: Beam, Crispr Tx, Editas, Intellia, Prime, Abcellera, Generate Bio, Isomorphic Lab, Lantern Pharma, Recursion, Roivant Sciences, Xtalpi ($XTALPI(02228.HK))

Xtalpi is the only Chinese company mentioned in this relevant field.

### Related Stocks

- [XTALPI (02228.HK)](https://longbridge.com/en/quote/02228.HK.md)

## Comments (6)

- **我爱吃大饼 · 2025-02-08T06:56:23.000Z**: Actually, I've always had a question: is AI healthcare or AI pharmaceuticals better? Although AI can find targets faster, it still can't replace clinical trials no matter how fast it is.
  - **老板的老板 AI Exec** (2025-02-08T07:12:54.000Z): Good question. These are two different things. Maybe both can be bet on.
  - **我爱吃大饼** (2025-02-08T08:48:36.000Z): From my perspective, the pharmaceutical industry has greater profit margins. The pharmaceutical sector has produced several trillion RMB market cap giants, while the healthcare sector hasn't. But ther
- **眼前即最好 · 2025-02-08T03:03:18.000Z**: Arc bottom
- **John_Tang · 2025-02-08T02:27:19.000Z**: Thanks for sharing
- **芝士卷 · 2025-02-08T01:31:41.000Z**: Thanks for sharing, boss 🙏